Stem Cells Spin Valuation

Is SCS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SCS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SCS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCS?

Key metric: As SCS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SCS. This is calculated by dividing SCS's market cap by their current revenue.
What is SCS's PS Ratio?
PS Ratio	42.1x
Sales	zł223.67k
Market Cap	zł9.42m

SCS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	42.4x
Enterprise Value/EBITDA	-30.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SCS's PS Ratio compare to its peers?

The above table shows the PS ratio for SCS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	16.4x
GEN Genomed Spólka Akcyjna	1.5x	n/a	zł34.4m
BER Bioerg Spólka Akcyjna	46.1x	n/a	zł13.8m
RDG Read-Gene	4.7x	n/a	zł55.1m
GX1 genXone	13.3x	n/a	zł23.1m
SCS Stem Cells Spin	42.1x	n/a	zł9.4m

Price-To-Sales vs Peers: SCS is expensive based on its Price-To-Sales Ratio (42.1x) compared to the peer average (6.5x).

Price to Sales Ratio vs Industry

How does SCS's PS Ratio compare vs other companies in the European Biotechs Industry?

37 Companies	Price / Sales	Estimated Growth	Market Cap

37 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SCS is expensive based on its Price-To-Sales Ratio (42.1x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is SCS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	42.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SCS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.